好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Measurement of Real-world Digital Mobility Outcomes in People With Various Levels of Multiple Sclerosis-related Disability
Multiple Sclerosis
P5 - Poster Session 5 (11:45 AM-12:45 PM)
18-004

To assess the relationships between research visit and real-world digital mobility outcome (DMO)-derived gait parameters and explore the correlations between DMOs and multiple sclerosis (MS)-related disability.

Over 75% of people with MS (pwMS) experience significant gait abnormalities, yet current gold-standard mobility assessments, such as timed walks, lack the sensitivity to detect subtle changes in gait mechanics. DMOs, derived from wearable sensors, may provide sensitive assessments of mobility impairment in clinical and real-world settings for pwMS.

Thirty adults with stable MS and Expanded Disability Status Scale (EDSS) score <6.5 were recruited from the Oregon Health & Science University MS clinic. Participants underwent a research visit assessing DMOs (i.e. 2 Minute Timed Walk [2MTW]) and patient reported outcomes (PROs) followed by seven days of real-world sensor measurements (worn on lumbar spine and bilateral ankles). Real-world DMO data was associated with research visit DMO data and patient reported outcomes (PROs) using Pearson correlations. The first 10 participants are presented here, and the rest of the cohort (n=30) will be included in the conference presentation.

The mean age of this cohort (n=10) was 55 years, 60% were female, and median EDSS score was 3.5 (2.5 - 6.5). Median EDSS of the entire cohort (n=30) was 5.0. Real-world increased average cadence was strongly and significantly correlated with longer 2MTW length during the research visit (r=0.69, p=0.04). Real-world 90th percentile cadence during walking bouts lasting over 30 seconds was strongly and significantly correlated with 2MTW increased average gait speed (p=0.73, p=0.04), increased average cadence (p=0.88, p=0.004), decreased average gait cycle duration (p=-0.89, p=0.003), and decreased average step duration (r=-0.89, p=0.003). There were significant associations between real-world average speed and MS Impact Scale (0.65, p=0.4).

Using sensors to measure real-world DMO could provide an accurate assessment of a participant’s average level of functioning across many ability levels.

Authors/Disclosures
Kristen Mittl
PRESENTER
Ms. Mittl has received research support from National Institute of Allergy and Infectious Diseases of the National Institutes of Health under Award Number R25AI179582.
Elizabeth Silbermann, MD (Oregon Health & Science University) Dr. Silbermann has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Neurology. Dr. Silbermann has received research support from VA.
Mac Day Mr. Day has nothing to disclose.
Caron Reeder (Oregon Health & Science University) No disclosure on file
Sean Pearson Mr. Pearson has received personal compensation for serving as an employee of Clario.
Jonathan Hogan, MD Dr. Hogan has received personal compensation for serving as an employee of Cabaletta Bio. Dr. Hogan has stock in Cabaletta Bio. Dr. Hogan has received intellectual property interests from a discovery or technology relating to health care.
Kristen Sowalsky, PhD, DC Dr. Sowalsky has nothing to disclose.
Mahmoud El-Gohary, PhD Mr. El-Gohary has received personal compensation for serving as an employee of Clario.
Lindsey B. Wooliscroft, MD (Oregon Health & Science University) The institution of Dr. Wooliscroft has received research support from National Institutes of Health.